Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ETH/BTC exchange rate bull James Fickel repaid a WBTC loan about 4 hours ago, with a loss of $68.84 million over the past year

ETH/BTC exchange rate bull James Fickel repaid a WBTC loan about 4 hours ago, with a loss of $68.84 million over the past year

Bitget2024/12/28 04:28

According to on-chain analyst Yu Jin's monitoring, ETH/BTC long position holder James Fickel sold 6,429 ETH ($21.45 million) four hours ago and exchanged it for 227 WBTC to repay all his WBTC loans.

James Fickel maintained a year-long long position on the ETH/BTC exchange rate, losing $68.84 million (20,632 ETH): In the first half of the year, he borrowed 2,987 WBTC through Aave at an exchange rate of 0.054 and sold them for 55,315 ETH to go long on the ETH/BTC exchange rate; starting in August, he gradually sold off ETH to buy back WBTC for repayment. He spent a total of 75,947 ETH at an exchange rate of 0.0393 to buy back and repay the 2,987 WBTC; ultimately incurring a loss of 20,632 ETH ($68.84 million) from going long on the ETH/BTC exchange rate.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss